Collegium Pharmaceutical Posts Record Quarterly Results, Shares Surge on Strong Earnings Beat

Collegium Pharmaceutical (COLL) delivered its strongest quarterly performance to date, reporting revenue of $138.4 million for the fourth quarter of 2025, a 22% year-over-year increase. Adjusted earnings per share reached $1.13, exceeding the consensus estimate of $1.02 by 10.8%. The company attributed the growth to increased volume and pricing strength for its branded opioid products, particularly Xtampza ER, which contributed $89.6 million in revenue during the quarter. The company’s gross profit margin expanded to 78.2%, reflecting improved manufacturing efficiencies and favorable product mix. Collegium also reported a net income of $58.3 million, up from $41.2 million in the same period the prior year. Operating expenses rose modestly to $58.9 million, driven by expanded sales and marketing initiatives in key U.S. markets. The strong financial results prompted a 19% surge in COLL stock price following the earnings release, with trading volume doubling its 30-day average. The rally has drawn attention from institutional investors and analysts, with several upgrading their ratings on the stock in the days following the report. Analysts highlighted the company’s ability to maintain pricing power amid regulatory scrutiny and increasing competition in the specialty pain segment. The performance underscores a broader trend of resilience in specialty pharmaceuticals with focused portfolios, particularly those managing complex regulatory environments. COLL’s success may prompt increased investor interest in similar mid-cap biotech firms with niche product lines and strong cash flow generation.